Role of angiotensin II in renal prostaglandin E2 production after furosemide administration.
The role of plasma angiotensin II (Ang II) in furosemide-stimulated renal prostaglandin E2 (PGE2) production was evaluated in eight healthy subjects. Urine was collected for 60 minutes after furosemide administration (20 mg i.v.) with or without captopril pretreatment, and urinary excretion of PGE2, sodium, and furosemide was determined. Plasma renin activity (PRA) and Ang II were also measured before and 60 minutes after furosemide administration. Urinary PGE2 excretion, PRA, and Ang II increased after furosemide administration without captopril pretreatment, and there was a significant correlation between the increment in Ang II and that in urinary PGE2 excretion. Urinary PGE2 excretion and Ang II did not increase after furosemide administration with captopril pretreatment. Urine volume and urinary excretion of sodium and furosemide were not influenced by captopril pretreatment. These results suggest that Ang II may play an important role in furosemide-stimulated PGE2 production.
Fujimura
A
A
Department of Clinical Pharmacology, Oita Medical School, Japan.
Ebihara
A
A
D000328:Adult; D000804:Angiotensin II / Q000502:physiology*; D002216:Captopril / Q000494:pharmacology; D015232:Dinoprostone; D005665:Furosemide / Q000494:pharmacology*; D006801:Humans; D007668:Kidney / Q000378:metabolism*; D008297:Male; D011458:Prostaglandins E / Q000096:biosynthesis* / Q000652:urine; D012083:Renin / Q000097:blood; D012964:Sodium / Q000652:urine; D014556:Urine
D011458:Prostaglandins E; D000804:Angiotensin II; D005665:Furosemide; D002216:Captopril; D012964:Sodium; D012083:Renin; D015232:Dinoprostone